EM Notes @ Jack CF Chong (張志華): Bicarbonate in Acute Kidney Injury

Bicarbonate in Acute Kidney Injury: Clinical Lecture Notes

1. Core Principle

Improving serum pH is a biochemical reaction, not proof that the underlying etiology is resolved.
Raising pH does not stop acid generation, eliminate accumulated acid anions, or guarantee improved clinical outcomes.
Avoid reflexively prescribing sodium bicarbonate simply because serum bicarbonate or pH is low.

Traditional Henderson-Hasselbalch model:
- Interprets pH through the balance between PaCO2 and serum HCO3-.
Stewart approach:
- Blood pH is governed by three independent variables:
  - PaCO2.
  - Strong Ion Difference (SID = strong cations minus strong anions, primarily Na+ minus Cl-).
  - Total nonvolatile weak acids (primarily albumin and phosphate).
- Serum HCO3- is a dependent variable, not an independent driver.
- Sodium bicarbonate acts by adding Na+ without a corresponding Cl-, thereby widening the SID and shifting the water dissociation equilibrium toward higher pH.
- Practical implication: Bicarbonate therapy modifies the strong ion balance rather than merely replacing a missing buffer.

Chemical reaction: HCO3- + H+ -> CO2 + H2O.
Each dose of bicarbonate generates an obligatory CO2 load that requires adequate alveolar ventilation to eliminate.
Risks in hypoventilating, exhausted, or poorly perfused patients:
- Systemic CO2 retention.
- Paradoxical intracellular and central nervous system acidification (lipophilic CO2 crosses cell membranes faster than charged HCO3-).
- Serum pH may improve while intracellular and organ tissue acidosis worsens.
- Correcting systemic acidemia blunts central respiratory drive, further aggravating hypoventilation.
Bedside rule: Always assess whether the patient has sufficient ventilatory reserve to clear the newly generated CO2.

Potential benefits:
- Temporarily mitigates severe acidemia-induced myocardial depression and vascular hyporesponsiveness.
- Promotes intracellular potassium shift in life-threatening hyperkalemia.
- Partially restores coagulation factor and platelet enzymatic function impaired by profound acidemia.
- Serves as a short-term bridge while arranging definitive etiology treatment or kidney replacement therapy.
Known adverse effects and risks:
- Hypernatremia and hyperosmolality from high-solute load.
- Volume overload and worsening pulmonary edema in oliguric AKI or heart failure.
- Acute drop in ionized calcium leading to myocardial dysfunction and tetany.
- Hypokalemia and associated cardiac arrhythmias.
- Metabolic alkalemia from overcorrection.
- Left shift of the oxyhemoglobin dissociation curve, impairing tissue oxygen release.
- Intracellular paradoxical acidosis from CO2 buildup.
- Blunted ventilatory drive.

Trial design: Multicenter randomized controlled trial of 389 critically ill ICU patients with severe metabolic acidemia (pH <= 7.20), comparing 4.2% sodium bicarbonate infusion (target pH >= 7.30) against control.
Primary outcome: No statistically significant difference in the overall composite endpoint of 28-day all-cause mortality and at least one organ failure by day 7.
Pre-specified AKI subgroup (AKIN Stage 2-3, n = 182):
- 28-day mortality was significantly lower in the bicarbonate arm (46% vs 63%).
- Requirement for kidney replacement therapy was significantly reduced (51% vs 73%).
Critical appraisal:
- Subgroup analyses are hypothesis-generating and carry risk of false-positive findings.
- Open-label design introduced potential clinician bias regarding triggers for initiating kidney replacement therapy.
- Do not interpret as a universal indication to give bicarbonate to every patient with AKI and acidemia.

Rational indications:
- Severe metabolic acidemia (pH < 7.15 to 7.20) in AKI with hemodynamic instability.
- Severe hyperchloremic metabolic acidosis alongside reduction of exogenous chloride intake.
- Critical hyperkalemia with concomitant metabolic acidosis as part of multimodal temporization.
- Documented severe bicarbonate-wasting states (severe diarrhea, RTA).
- Short-term bridging while preparing for emergent kidney replacement therapy.
Frequent misuses:
- Infusing bicarbonate instead of restoring volume, perfusion, and microcirculation in circulatory shock.
- Repeated sodium loading in patients with heavy unmeasured anion accumulation.
- Administering bicarbonate to patients with ventilatory failure without airway or mechanical ventilatory support.
- Overlooking cumulative sodium load in hypervolemic or severely oliguric patients.
- Chasing normal laboratory numbers rather than modest physiological stabilization.
- Relying on bicarbonate infusions to delay needed kidney replacement therapy.

Step 1: Assess severity. Review pH, PaCO2, HCO3-, hemodynamic parameters, rhythm, and potassium level.
Step 2: Determine mechanism. Calculate anion gap; evaluate chloride, lactate, ketones, albumin, and renal function.
Step 3: Check ventilatory capacity. Verify whether spontaneous minute ventilation or mechanical ventilation can clear the extra CO2 burden.
Step 4: Consider definitive alternatives. Restore tissue perfusion, stop chloride loading, manage sepsis or diabetic ketoacidosis, or initiate kidney replacement therapy.
Step 5: Administer fractionated doses with discrete endpoints. Use small, incremental infusions; target a pH of roughly 7.20 to 7.25 rather than normal values; serial re-evaluation of blood gases, electrolytes, and ionized calcium is mandatory.

Serum HCO3- is a dependent variable; sodium bicarbonate functions by expanding the strong ion difference.
Bicarbonate infusion produces CO2; adequate alveolar ventilation is required.
Improving pH is not equivalent to treating the underlying cause.
Clearing accumulated unmeasured anions in severe AKI requires kidney replacement therapy, not additional sodium load.